-
Akhmetzyanova I, Drabczyk M, Neff CP, Gibbert K, Dietze KK, Werner T, Liu J, Chen L, Lang KS, Palmer BE, Dittmer U, Zelinskyy G, 2015: PD-L1 expression on retrovirus-infected cells mediates immune escape from CD8+ T cell killing[J]. PLoS Pathog, 11, e1005224-. doi: 10.1371/journal.ppat.1005224
-
Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R, 2006: Restoring function in exhausted CD8+ T cells during chronic viral infection[J]. Nature, 439, 682-687. doi: 10.1038/nature04444
-
Bengsch B, Martin B, Thimme R, 2014: Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J]. J Hepatol, 61, 1212-1219. doi: 10.1016/j.jhep.2014.07.005
-
Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C, 2007: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection[J]. J Virol, 81, 4215-4225. doi: 10.1128/JVI.02844-06
-
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL, 2010: Phase Ⅰ study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. J Clin Oncol, 28, 3167-3175. doi: 10.1200/JCO.2009.26.7609
-
Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK, 2018: Circulating and intrahepatic antiviral B cells are defective in hepatitis B[J]. J Clin Investig, 128, 4588-4603. doi: 10.1172/JCI121960
-
Dietze KK, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U, 2013: Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virusspecific CD8+ T cells and efficiently reduces chronic retroviral loads[J]. PLoS Pathog, 9, e1003798-. doi: 10.1371/journal.ppat.1003798
-
Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini EM, Andreone P, Missale G, Ferrari C, 2010: Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B[J]. Gastroenterology, 138, 682-693. doi: 10.1053/j.gastro.2009.09.052
-
Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A, Ahmed R, Walker CM, 2013: Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)[J]. Proc Natl Acad Sci USA, 110, 15001-15006. doi: 10.1073/pnas.1312772110
-
Gane E, Gaggar A, Nguyen AH, Subramanian GM, McHutchison JG, Schwabe C, Dunbar R, 2017: A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients[J]. J Hepatol, 66, S26-S27.
-
Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I, 2013: A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection[J]. PLoS ONE, 8, e63818-. doi: 10.1371/journal.pone.0063818
-
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K-, 2015: Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 372, 2018-2028. doi: 10.1056/NEJMoa1501824
-
Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM, Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ, Team ACTS, 2017: Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy[J]. J Infect Dis, 215, 1725-1733. doi: 10.1093/infdis/jix191
-
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A, 2013: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma[J]. N Engl J Med, 369, 134-144. doi: 10.1056/NEJMoa1305133
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ, 2010: Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 363, 711-723. doi: 10.1056/NEJMoa1003466
-
Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai WP, Heraud JM, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G, 2006: CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques[J]. Blood, 108, 3834-3842. doi: 10.1182/blood-2006-04-010637
-
Ishida Y, Agata Y, Shibahara K, Honjo T, 1992: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 11, 3887-3895. doi: 10.1002/embj.1992.11.issue-11
-
Jeon S, Rowe AM, Carroll KL, Harvey SAK, Hendricks RL, 2018: PD-L1/B7-H1 inhibits viral clearance by macrophages in HSV-1-infected corneas[J]. J Immunol, 200, 3711-3719. doi: 10.4049/jimmunol.1700417
-
Kaufmann DE, Walker BD, 2009: PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention[J]. J Immunol, 182, 5891-5897. doi: 10.4049/jimmunol.0803771
-
Krummel MF, Allison JP, 1995: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation[J]. J Exp Med, 182, 459-465. doi: 10.1084/jem.182.2.459
-
Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP, 1997: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer[J]. Proc Natl Acad Sci USA, 94, 8099-8103. doi: 10.1073/pnas.94.15.8099
-
Leach DR, Krummel MF, Allison JP, 1996: Enhancement of antitumor immunity by CTLA-4 blockade[J]. Science, 271, 1734-1736. doi: 10.1126/science.271.5256.1734
-
Ledford H, Else H, Warren M, 2018: Cancer immunologists scoop medicine Nobel prize[J]. Nature, 562, 20-21.
-
Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, Moller I, Seiz P, Glebe D, Wang B, Yang D, Lu M, Roggendorf M, 2014: Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection[J]. PLoS Pathog, 10, e1003856-. doi: 10.1371/journal.ppat.1003856
-
Palmer BE, Neff CP, Lecureux J, Ehler A, Dsouza M, RemlingMulder L, Korman AJ, Fontenot AP, Akkina R, 2013: In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice[J]. J Immunol, 190, 211-219. doi: 10.4049/jimmunol.1201108
-
Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, Pavlik DF, Rodriguez-Garcia M, Pereyra F, Freeman GJ, Kavanagh DG, Kaufmann DE, 2011: Responsiveness of HIV-specific CD4 T cells to PD-1 blockade[J]. Blood, 118, 965-974. doi: 10.1182/blood-2010-12-328070
-
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ, 2014: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer[J]. Nature, 515, 558-562. doi: 10.1038/nature13904
-
Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A, 2018: PD-1 blockade partially recovers dysfunctional virusspecific B cells in chronic hepatitis B infection[J]. J Clin Investig, 128, 4573-4587. doi: 10.1172/JCI121957
-
Sanmamed MF, Chen L, 2018: A paradigm shift in cancer immunotherapy: from enhancement to normalization[J]. Cell, 175, 313-326. doi: 10.1016/j.cell.2018.09.035
-
Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, Nebbia G, Kennedy PT, Geretti AM, Dusheiko G, Maini MK, 2011: Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection[J]. Hepatology, 53, 1494-1503. doi: 10.1002/hep.24249
-
Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM, 2013: PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads[J]. PLoS ONE, , e77780-.
-
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS, 2014: Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab[J]. J Clin Oncol, 32, 1020-1030. doi: 10.1200/JCO.2013.53.0105
-
Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ, Ahmed R, Amara RR, 2009: Enhancing SIV-specific immunity in vivo by PD-1 blockade[J]. Nature, 458, 206-210. doi: 10.1038/nature07662
-
Wykes MN, Lewin SR, 2018: Immune checkpoint blockade in infectious diseases[J]. Nat Rev Immunol, 18, 91-104.
-
Zhang E, Zhang X, Liu J, Wang B, Tian Y, Kosinska AD, Ma Z, Xu Y, Dittmer U, Roggendorf M, Yang D, Lu M, 2011: The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection[J]. PLoS ONE, 6, e26196-. doi: 10.1371/journal.pone.0026196